MedWatch

Investors fear share emission from debt-heavy GN

The hearing group has lost 70% of its stock value this year, and analysts say this is because shareholders are worrying about the company’s large debt.

Photo: GN Store Nord / PR

A fear of dilution should GN Group, the parent organization under which hearing aid manufacturer GN Hearing resides, need to raise capital is weighing down the company’s stock, according to a number of analysts that Danish media Finans has spoken with.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs